China's medical products administrator approved Nanjing King-Friend Biochemical Pharmaceutical's (SHA:603707) drug registration for its fulvestrant injection for breast cancer, according to a Tuesday filing with the Shanghai Stock Exchange.
The drug is indicated for post-menopausal estrogen-receptor-positive locally advanced or metastatic breast cancer that relapses following or during anti-estrogen adjuvant therapy, the filing said.
The injection is used simultaneously with abemaciclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer, among other types, the filing said.
Shares closed 2% higher during Tuesday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.